Third Quarter Financial Statement

Condensed unaudited interim consolidated financial statements of Helix BioPharma Corp. for the three and nine month periods ended April 30, 2016 and 2015

Helix BioPharma Corp. Announces CEO Change

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” or the “Company” and listed on TSX & FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Zbigniew Markowski will be stepping down, for personal and family reasons, from his positions as Chief Executive Officer of Helix BioPharma Corp and …

Helix BioPharma Corp. Reports on Advancement of Its L-DOS47 Phase I/II Study in Poland

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Registration Office of Medicinal Products, Medical Devices and Biocides in Poland and the Bioethics Committee has approved an amendment to the Phase I/II study (“LDOS002”) defining the dose and dosing regimen for the …

Helix BioPharma Corp. Reports on Advancement of its Lung Cancer Drug Candidate L-DOS47

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the Trial Steering Committee has completed a review of safety data and recommended the opening of patient screening for the sixteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 …

Changes in the Leadership of Helix Polska

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces changes in the leadership team of its Polish subsidiary “Helix Polska”. The appointments are effective as of January, 28, 2016.

Helix BioPharma Corp Announces Appointment of New Directors to the Board of Directors

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, has today announced the appointment of Mr. Albert Beraldo and Mr. George J. Anders to the board of directors. The appointments are effective as of January 28, 2016. At the same time, Mr. Gary Littlejohn and Mr. Yvon …

Helix BioPharma Corp Initiates Enrollment In The Second Dosing Cohort Of U.S. Combination Treatment Study Of Its Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the second dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin (“LDOS001”).

Helix BioPharma Corp Announces Appointment of Permanent New CEO and Changes at Board Level

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” or the “Company” and listed on TSX & FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that it has appointed Dr. Zbigniew Markowski as Chief Executive Officer, replacing Mr. Gary Littlejohn who was serving as Interim CEO.

Helix BioPharma Corp Signs License Agreement with Helix Polska to Develop Cancer Therapies in Poland

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” and listed on TSX & FSE: “HBP”) (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has granted a world-wide exclusive license for v-DOS47, an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor …